Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors

    Receive Latest News

    Feedburner
    Share Us


    WHY IS FDA AT MY FACILITY, AND WHAT DO I DO DURING 2017 - Why is FDA at my facility, and what do I do during an inspection 2017

    View: 129

    Website http://www.globalcompliancepanel.com/control/globalseminars/~product_id=900762SEMINAR?channel=mailer | Want to Edit it Edit Freely

    Category Clinical Trials Regulation

    Deadline: April 06, 2017 | Date: April 06, 2017-April 07, 2017

    Venue/Country: Baltimore,MD, U.S.A

    Updated: 2017-03-01 20:06:52 (GMT+9)

    Call For Papers - CFP

    Course "Why is FDA at my facility, and what do I do during an inspection" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.

    Overview:

    Many regulated companies preparing for FDA inspections are not prepared and the outcome can be negative as we see all the time with enforcement actions. This seminar provides the fundamentals and the ground rules on how to prepare for and survive an FDA inspection no matter if you are a Class I, II, III device or a pharmaceutical or biologics manufacturer. This presentation will review and emphasize the do's and don'ts and cardinal rules as to interviewing, how to respond, reviewing documentation, etiquette, use of certain words, body language, responding to questions/requests, etc., and certainly replying to 483's and Warning Letters. Emphasis is placed on the company's SOP on dealing with inspectors and knowing how to be prepared, proactive...and being able to defend and justify... and what it takes to achieve a favorable outcome. This seminar provides background and understanding of the role played by the Agency, its administrative and enforcement powers. It takes the participant step by step through the entire inspection process and describes various types of inspections.

    Who will benefit:

    Industries

    FDA regulated Industries

    Medical Device

    Pharmaceuticals

    Clinical

    Dietary Supplements

    Food

    Nutraceutical

    Healthcare IT

    Technical Services

    Validation

    Engineering

    Small Business Owners

    Departments

    Top and Middle Management

    Quality Assurance/Management

    Compliance Management

    Manufacturing

    Laboratory

    Regulatory Affairs

    Information Technology

    Marketing & Sales

    Operations

    Research & Development

    Types of facilities:

    Manufacturing facilities

    Contract manufacturing facilities

    Distributors

    Packaging, Labeling

    API Suppliers

    Laboratories

    Importers

    Documentation Management

    Agenda:

    Lecture 1:

    How a firm should prepare for an FDA inspection

    Lecture 2:

    Ways to train employees in view of the inspection

    Lecture 3:

    How to ensure that required documentation is in place

    Lecture 4:

    How to interact with the investigator-DO's and DON'T's

    Lecture 5:

    What companies should do when the inspection ends

    Lecture 6:

    How to reply to 483's and warning letters

    Lecture 7:

    Legal implications of non-compliance

    Lecture 8:

    Post inspection actions

    Day 2 Schedule

    Lecture 1:

    Why inspections are conducted and by what statutory authority

    Lecture 2:

    The emphasis on systems-based inspections...and the IOM and other crucial FDA reference documents

    Lecture 3:

    What is subject to FDA purview and what's off-limits

    Lecture 4:

    Understand and apply the do's and don'ts and comprehend that preparation is the key to success

    Lecture 5:

    What are the prohibited "Acts" and the enforcement categories that you need to deal with

    Lecture 6:

    What you need to know and do to prepare for, during and even after the inspection...and why your inspection response team is key

    Lecture 7:

    The company's Inspection Plan (SOP) can make or break the inspection depending on how to use it and training your personnel

    Lecture 8:

    How to respond to findings and facilitating the documentation and remediation process...and reaching final closure

    Lecture 9:

    Define clear responsibilities, roles and goals for personnel involved in SOP development

    Speaker:

    David R. Dills,

    Regulatory Affairs & Compliance Consultant.

    David R. Dills, Global Regulatory Affairs & Compliance Consultant, has an accomplished record with more than 26 years of experience within regulatory affairs, compliance and quality consultative services for early-stage/established Class I/II/III medical devices, IVDs, and bio/pharmaceutical manufacturers on the global landscape. Previously employed, with increasing responsibilities by device manufacturers and consultancies, including a globally recognized CRO, has worked directly with and for manufacturers engaged in compliance remediation activities involving consent decrees, CIA's, FDA warning letters, and customer generated compliance events, provides Strategic GxP Compliance and Regulatory Consulting, handles all aspects of global regulatory submissions and dossiers, including 510(k), PMA, Design Dossiers, Technical Files, CMC, NDA, and IDE submissions, currently serves as a U.S. Agent, works with stakeholders and Center Reviewers regarding submission meetings/negotiations, clinical affairs, and provides regulatory submissions and post-market project leadership/guidance covering different therapeutic and medical specialties based on classification. His background encompasses broad capabilities in regulatory and compliance oversight and governance, including CAPA, Design Controls, Validation, Software Quality with regulatory oversight, FDA Mock Inspections, remediating documentation management systems, Supplier Quality, Adverse Event Reporting, Product Complaints, GxP Training, interpretation and applicability of FDA and international regulations and standards, post marketing surveillance, ISO 13485 and CE Mark, Medical Device/IVD/Active Implantable Directives. Mr. Dills leads and manages efforts involving multi-country product registrations and licensing in Asia Pacific, EMEA and The Americas from premarketing to post marketing, and works with the Regulatory Authorities and strives to provide consistent, practical compliance solutions that work with reduction of regulatory compliance risk.

    Location: Baltimore, MD Date: April 6th & 7th, 2017 and Time: 9:00 AM to 6:00 PM

    Venue: The DoubleTree Baltimore-BWI Airport

    Address: The DoubleTree Baltimore-BWI Airport 890 Elkridge Landing Road - Linthicum, MD 21090

    Price:

    Register now and save $200. (Early Bird)

    Price: $1,295.00 (Seminar Fee for One Delegate)

    Until February 28, Early Bird Price: $1,295.00 from March 01 to April 04, Regular Price: $1,495.00

    Register for 5 attendees Price: $3,885.00 $6,475.00 You Save: $2,590.00 (40%)*

    Quick Contact:

    NetZealous DBA as GlobalCompliancePanel

    Phone: 1-800-447-9407

    Fax: 302-288-6884

    Email: supportatglobalcompliancepanel.com

    Follow us on LinkedIn: https://www.linkedin.com/company/globalcompliancepanel?

    Like us our Facebook page: https://www.facebook.com/TrainingsAtGlobalCompliancePanel/

    Follow us on Twitter: https://twitter.com/GCPanel


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.